BIOA BIOAGE LABS INC.

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.

TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on various aspects of the health care industry.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel, structurally differentiated APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil,

IR: Dov Goldstein,

Partnering:

Web:



EN
20/02/2025

Underlying

BIOABIOAGE LABS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOAGE LABS INC.

 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports First Quarter 2025 Financial Results and Provides ...

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic dise...

May 6, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Reports Full Year 2024 Financial Results and Provides Busi...

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candida...

March 20, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Confe...

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in Boston, MA. The con...

February 20, 2025 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Prog...

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Comp...

January 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch